Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults with Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (alone or with Pioglitazone and/or SGLT2 inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period

Next Previous
Trial Profile

A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults with Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (alone or with Pioglitazone and/or SGLT2 inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Albiglutide; Dulaglutide; Exenatide; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms LixiLan-G
  • Sponsors Sanofi

    • Most Recent Events

    • 22 Feb 2024 Results of pooled analysis of four studies (LixiLan-O, LixiLan-G, LixiLan-L, SoliMix) assessing efficacy and safety of iGlarLixi in older people (≥65 years) with type 2 diabetes (T2D) advancing or switching from oral agents, published in the Diabetes, Obesity and Metabolism.
    • 26 Jun 2023 Results of a post-hoc pooled analysis assessing factors associated with achieving target HbA1c <7.0% in people with type 2 diabetes treated with iGlarLixi from four clinical trials: NCT02058147, NCT02058160, NCT02787551 and EudraCT2017-003370-13 presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
    • 26 Jun 2023 Results (n=465) of a post-hoc pooled analysis assessing predictors of glycemic control in older people with type 2 diabetes treated with iGlarLixi from following clinical trials: NCT02058147, NCT02058160, NCT02787551 and EudraCT2017-003370-13 presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top